Diagnostic applications of cell-free and circulating tumor  cell-associated miRNAs in cancer patients by Mostert, B. (Bianca) et al.
 1
Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients 
 
Bianca Mostert1, Anieta M. Sieuwerts2, John W.M. Martens2, Stefan Sleijfer1 
 
Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, 
Netherlands 
1Daniel den Hoed Cancer Center, Laboratory of Clinical Tumor Immunology 
2Josephine Nefkens Institute and Cancer Genomics Centre 
 
Bianca Mostert 
Erasmus MC, Daniel den Hoed Cancer Center, Room D2-62 
Groene Hilledijk 301 
3075 EA Rotterdam 
Netherlands 
Tel.: +31 10 7041324 




Anieta M. Sieuwerts  
Erasmus MC, Josephine Nefkens Institute, Room BE-400 
Dr. Molewaterplein 50 
3015 GE Rotterdam 
Netherlands 
Tel.: +31 10 7044372 
Fax: +31 10 7044377 
Email: a.sieuwerts@erasmusmc.nl 
 
John W.M. Martens 
Erasmus MC, Josephine Nefkens Institute, Room BE-400 
Dr. Molewaterplein 50 
3015 GE Rotterdam 
Netherlands 
Tel.: +31 10 7044372 




Erasmus MC, Daniel den Hoed Cancer Center, Room G4-83 
Groene Hilledijk 301, 
3075 EA Rotterdam 
Netherlands 
Tel: +31 10 7041331 




Circulating tumor cells (CTCs) have rapidly developed as important cancer biomarkers after their enumeration 
proved to be prognostic in metastatic breast, colorectal and prostate cancer, and their rise or decline after the 
first cycle of therapy showed to predict therapy response. Besides mere counting, CTCs can be isolated and 
subsequently analyzed using various molecular applications, including miRNA expression analysis. Recently, 
miRNA expression profiling in primary tumors has yielded promising results. However, establishing miRNA 
expression in the circulation likely has advantages over determination in primary tumor tissue, further 
augmenting the potential applications of miRNA determination in oncology. Additionally to CTC-associated 
miRNAs, free circulating miRNAs have been identified in whole blood, plasma and serum.  
Since determination of miRNAs in peripheral blood, either cell-free or CTC-associated, is expected to become 
important in oncology, especially when linked to and interpreted together with epithelial CTCs, this review 
focuses on measuring miRNAs in the circulation of cancer patients. 
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1. Introduction 
The implementation of assays enabling the detection of circulating tumor cells (CTCs) has sparked an 
additional boost of interest in blood-derived biomarkers for cancer patients. Numerous assays for CTC 
enumeration have been described lately and for one, the CellSearch™ Epithelial Cell test (Veridex LCC, 
Raritan, NJ), FDA-approval has been acquired for use as a prognostic factor when measured in patients with 
metastatic breast[1,2], colorectal[3] and prostate cancer[4]. Additionally to its application as a prognosticator 
prior to treatment start, enumeration of CTCs may also guide treatment decisions, as a rise or decline in the 
number of CTCs after the first cycle of chemotherapy predicts for therapy response earlier than conventional 
radiographic evaluation does[5].  
Probably even more interesting than mere counting, CTCs can be isolated from the blood of cancer patients for 
further analysis. In the case of metastatic disease, analysis of metastatic tissue can be very informative. Often, 
a considerable amount of time has passed since the occurrence and resection of the primary tumor and in 
many cases systemic adjuvant treatment has been administered. This means that clinically relevant changes 
can have occurred in the geno- and phenotype of residual cancer cells, and these changes could and probably 
should affect treatment decisions. Therefore, characterization of metastatic tissue, rather than that of the 
primary lesion, may show a better association with outcome in cancer patients.  
Clinicians are however understandably reluctant to perform invasive and complicated procedures to obtain 
tissue from patients for whom quality of life is a major concern. The isolation and subsequent characterization 
of CTCs provide the opportunity to bypass the problems associated with obtaining metastatic tissue, and serve 
as a ‘liquid biopsy’. CTCs have already been characterized for presence of gene amplification[6-8] and genetic 
aberrations[9,10], for expression of proteins[11] and several mRNAs[12-14], and recently, also for expression of 
certain miRNAs(submitted manuscript).  
In recent years, miRNAs have been revealed as key regulators of gene expression. Given this crucial role, it is 
not surprising that miRNA expression in primary tumor tissue associates with outcome in several studies. 
However, determination of miRNA expression in the peripheral circulation, either CTC-associated or as cell-free 
circulating molecules, likely has several advantages over determination in primary tumor tissue, thereby further 
augmenting the potential applications of miRNA determination in oncology. 
In this review, we will discuss the measurement of cell-free and CTC-associated miRNAs present in the 




MiRNAs (miRs) are small single-stranded RNA molecules, measuring 21-23 nucleotides in length, which have, 
since their discovery in 1993[15], been shown to play important roles in regulating gene expression[16]. Until 
recently, miRNAs were disregarded as degraded RNA fragments or non-translated small RNAs, but the 
discovery of their aberrant expression in a wide array of pathological events and their involvement in 
carcinogenesis has made them a hot topic in cancer research[17,18]. One of the big advantages of miRNAs is 
their stability, and it has been shown that cell-free miRNAs in body fluids are stable under harsh conditions 
such as high temperatures, extreme pH values, repeated freeze-thaw cycles and long-term storage[19-
24].They are well preserved, not only in blood, but also in tissues that have been formalin-fixed and paraffin-
embedded years before[25]. This enables the retrospective analysis of large tissue collections, providing 
researchers with massive amounts of information. The identification of miRNAs has yielded an exciting new 
array of easy accessible molecular features, which may be employed in diagnostic and therapeutic decision 
making in cancer patients. 
 
2.1 MiRNA biology 
In the nucleus, miRNAs are transcribed by RNA polymerase II into large polyadenylated, capped primary 
miRNA transcripts (pri-miRNAs)[18,26] (Figure 1). These pri-miRNAs are subsequently cleaved by a complex 
formed by the RNAse II enzyme Drosha and its binding partner DGCR8 (DiGeorge syndrome critical region 8, 
or Pasha) into precursor miRNAs (pre-miRNAs). These pre-miRNAs are 70-90 nucleotides in length and have 
an imperfect stem loop hairpin structure. They are transported into the cytoplasm by Exportin 5 where the 
hairpin precursors are cleaved by a complex formed by the RNAse III enzyme Dicer and its binding partner 
TRBP (HIV-1 transactivating response RNA binding protein); resulting in a small dsRNA duplex that contains 
both the mature miRNA strand and its complementary strand. The mature miRNA strand is then incorporated 
into a RNA-induced silencing complex (RISC), which inhibits the function of its target mRNA by mRNA 
degradation or, most commonly, by translational repression after binding of the RISC to the target mRNA. 
Additionally, miRNAs can increase the expression of their target mRNA[18,27]. 
 
2.2 MiRNA function 
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MiRNAs are estimated to regulate up to 30% of all protein-coding genes[28]. They regulate post-transcriptional 
gene expression in a sequence-specific manner, recognizing their mRNA target with the 5’-end of the mature 
miRNA strand, which is often referred to as the ‘seed-sequence’[29]. After recognition of the target mRNA, 
regulation of gene expression can occur through two different mechanisms, depending upon the 
complementarity of the miRNA sequence with its target mRNA. When perfect base-paring homology exists 
between the miRNA and the mRNA, the RNA-mediated interference pathway is induced, which leads to 
cleavage of the mRNA by Argonaute, present in the RISC complex. When imperfect binding to partially 
complementary sequences in the 3’-untranslated region of target mRNAs occurs, which is more frequent than 
perfect binding, the target mRNA is regulated by repression of protein translation. Consequently, proteins are 
regulated by miRNAs without significantly affecting the corresponding mRNA expression levels. Such 
knowledge underscores the need to combine mRNA and miRNA data to generate improved predictive and 
prognostic models. 
 
3. MiRNAs in primary cancer and their potential applications 
MiRNAs are thought to play two distinctly different roles in carcinogenesis, functioning both as ‘oncomirs’ and 
as tumor suppressors. This hypothesis is supported by the observation that miRNA expression in tumors can 
be up- or downregulated compared to normal tissue[30]. The miRNA expression profiling of tumors has 
provided many new insights into states of differentiation and lineages within different tumor types. 
As a consequence of the crucial role of miRNAs in tumor biology, there is a broad range of potential 
applications of miRNA measurement in oncology. Besides being informative of tumor biology, miRNA 
signatures can also be a diagnostic tool, serve as prognostic factors, predictive factors, potential drug targets 
and as pharmacodynamic markers. All of these applications are possible in primary tumors and metastases, but 
the stability of miRNAs also enables their detection in the circulation. In this field, circulating miRNAs can serve 
as biomarkers that can be measured repeatedly and non-invasively in a wide array of cancer types. 
Research to date has however mainly focused on primary tumor tissue. We will, without attempting to give a 
complete overview, provide examples of miRNAs being used as any of the aforementioned biomarkers. 
 
3.1 MiRNAs to identify cancer tissue origin 
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MiRNAs can serve to determine the tissue of origin for cancers of unknown primary origin, as has been shown 
with a classifier based on 48 miRNAs[31,32]. This microarray-based classifier was generated on 205 primary 
tumors and 131 metastases of 22 different tumor origins. The classifier was validated in an independent test 
set, in which it reached an overall sensitivity of 72% and a specificity of 99%. This application could be very 
informative in the still existing problem of metastatic cancer patients in whom no primary tumor can be 
identified, and for whom no standard chemotherapy exists. 
 
3.2 MiRNA expression profiles to classify cancers 
Lu and co-workers showed that miRNA profiles are surprisingly informative, reflecting the developmental 
lineage and differentiation state of the tumors. They not only observed a general down regulation of miRNAs in 
tumors compared to normal tissues, but were also able to successfully classify poorly differentiated tumors 
using miRNA expression profiles. Contrarily, messenger RNA profiles were highly inaccurate in classifying 
tumors when applied to the same samples[30]. Breast cancer is a notoriously heterogeneous disease, but 
miRNAs can help to identify the subtype origin of tumor cells, as was demonstrated by Sempere and co-
workers using an in situ hybridization method to reveal the spatial distribution of miRNA expression in archived 
formalin-fixed, paraffin-embedded breast tumors[33]. 
 
3.3 MiRNAs as prognostic factors 
Many investigators have focused on identifying miRNAs that can separate patient groups according to 
prognosis. It would be beyond the scope of this review to discuss all studies that have identified such 
prognostic miRNAs, and we refer to Ferracin et al.[34] for a complete and comprehensive overview. 
 
3.4 Predictive miRNAs 
Not many data have been generated identifying specific miRNAs that can predict response to systemic therapy. 
This is not surprising, as determining true predictive value of a miRNA requires studies designed very carefully 
specifically for that research question.  
3.4.1. Ovarian cancer 
In ovarian cancer, miR-214 has been identified as a miRNA involved in resistance to cisplatin, through targeting 
of PTEN[35]. In this study, 4 of the most differentially expressed miRNAs among a total of 515 miRNAs tested 
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in 10 ovarian tumors and 10 normal cell line pools were further validated. MiR-214 was one of the most 
frequently upregulated miRNAs in 30 primary ovarian tumors; and its role in cisplatin resistance was elucidated 
by knocking down miR-214, causing increased PTEN protein expression and decreased Akt phosphorylation. 
Furthermore, the expression of miR-214 in miR-214-negative cell lines led to resistance to cisplatin-induced cell 
death, and subsequent knockdown of miR-214 resulted in increased sensitivity to cisplatin-induced cell 
death[35]. These promising results should be validated in patients treated with cisplatin before miR-214 can be 
used as a valid biomarker to predict cisplatin response.  
3.4.2 Non-small cell lung cancer 
This validation in patient samples was performed in a study looking at the predictive value of miR-128b 
expression on response to gefitinib, an EGFR inhibitor, in non-small cell lung cancer (NSCLC)[36]. MiR-128b 
was chosen based on its regulatory role for EGFR and the fact that loss of chromosome 3p, where miR-128b is 
located, is one of the most frequent and earliest events in lung carcinogenesis. An inverse relationship between 
miR-128b and EGFR expression was observed in NSCLC cell lines, and while EGFR expression as assessed 
by immunohistochemistry did not correlate with gefitinib response in 58 NSCLC patients, EGFR mutations and 
loss of miR-128b were associated with improved response to gefitinib. In multivariate analysis, only histology, 
line of treatment and loss of miR-128b, and not EGFR expression or mutation, were found to be predictive of 
response[36]. 
3.4.3. Hepatocellular carcinoma (HCC) 
Ji et al. undertook a carefully designed study in three independent cohorts of a total of 455 HCC patients, and 
identified miR-26 to be lower expressed in tumors than in paired noncancerous tissue[37]. Additionally, of the 
patients who were not treated with interferon, the control arm of the cohorts, those with lower expression of 
miR-26 in their tumor had a shorter overall survival. Contrarily, of the patients in the treatment arm of the 
cohorts who did receive interferon, those with lower miR-26 expression had an improved survival compared to 
patients with higher miR-26 expression. In multivariate analysis too, a significant interaction was observed 
between miR-26 expression and response to interferon therapy[37]. 
3.4.4 Breast cancer 
While data have been generated on breast cancer cell lines[38,39] we recently selected 5 candidate predictive 
miRNAs from 249 miRNAs measured in a small discovery set of breast cancer specimens and analyzed their 
expression in an independent series of 246 ER-positive primary breast tumors. In multivariate analysis, higher 
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expression of miR-30c was associated with benefit from first line tamoxifen monotherapy and longer 
progression-free survival[40].  
 
3.5 MiRNAs as drug targets 
Because of their pivotal role in cancer development, progression and treatment, several preclinical findings 
point at the great potential to use miRNA as drug targets, either by inhibiting overexpressed ‘oncomirs’ or 
replacing underexpressed tumor suppressor miRNAs. Inhibition of miR-21 has been shown to reduce tumor 
development and metastatic potential in breast cancer cells[41]. Inhibition of miR-21, combined with miR-200b, 
also enhanced response to gemcitabine in cholangiocarcinoma cells[42]. In breast cancer cells, reintroducing 
miR-205 resulted in improved response to tyrosine kinase inhibitors through HER3 silencing[43]. 
Finally, researchers have demonstrated that hepatocellular carcinoma cells have reduced expression of miR-
26, while this miRNA is highly expressed in normal tissues. Re-expression of miR-26 caused cells to arrest in 
G1, probably through repression of cyclin D2 and cyclin E2. When administering miR-26 to a mice model using 
a adeno-associated viral vector, cancer cell proliferation was reduced and apoptosis increased[44].  
 
4. Measuring miRNAs in the circulation 
As depicted above, promising results have been obtained in primary tumor material with respect to miRNAs as 
cancer biomarkers. There are however a number of situations in which it is likely that the value of miRNAs can 
be further augmented by measuring miRNAs in blood, either as cell-free circulating miRNAs or as CTC-
associated miRNAs. Below we will discuss the potential applications of circulating miRNAs. 
4.1 Circulating miRNAs can help to more accurately predict patient outcome 
Many studies have focused on identifying prognostic miRNAs in primary tumors, and these prognostic factors 
are now known for a large variety of tumor types. While these prognostic miRNAs do distinct those patients with 
a favorable outcome from those with an unfavorable outcome, measuring miRNAs in the primary tumor does 
not take into account two important things; not all cells in the primary tumor have the ability to metastasize, and 
the subset of spreading tumor cells might differ in genetic make-up. Secondly, at the time of metastatic disease, 
genetic characteristics of the remaining or relapsing tumor cells can differ from those of the primary tumor, 
because by the time a patient presents with metastatic disease, years might have gone by since first 
presentation, and various different anti-tumor treatments can have been administered. Both these factors can 
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cause profound differences in genetic and epigenetic make-up between primary tumor and metastatic tissue. At 
the time of disseminated disease, optimally, metastatic tissue would be used to determine prognosis; however, 
acquiring such tissue can often only be done through painful and invasive procedures. Circulating tumor cells 
can serve as a ‘liquid biopsy’ representing the patient’s tumor load, and thereby provide a unique opportunity to 
assess prognosis in real time. 
Furthermore, the presence of miRNAs that are associated with the process of metastasis or epithelial-to-
mesenchymal transition, a process that is thought to be necessary for haematogenous spread of disease to 
occur, might identify those patients that already have distant micrometastases too small to diagnose otherwise. 
 
4.2 Circulating miRNAs to predict response to anti-tumor therapy 
When systemic therapy is warranted, either in the adjuvant or metastatic setting, the choice of first line 
treatment can be crucial for ultimate patient outcome. Depending on tumor type, various patient and tumor 
characteristics are taken into consideration when deciding on the optimal treatment, but still, for a proportion of 
patients, ineffective therapy is started. Especially in patients receiving targeted therapy, such as EGFR 
inhibitors, factors determining their benefit are still being discovered. While most attention has been given to 
predictive factors such as KRAS mutations and EGFR expression, it may be expected that miRNAs will turn out 
to play an equally important role, given their pivotal role in cancer progression. As discussed before, circulating 
miRNAs can be measured repeatedly, which is especially important for their use as a predictive factor. One can 
imagine wanting to administer a certain systemic therapy as second-line treatment, for which a predictive 
miRNA has been established. While this miRNA can be measured in the primary tumor, earlier administered 
systemic therapy can have affected the expression of this miRNA in residual cancer cells. It is, therefore, very 
conceivable that a treatment adapted to circulating tumor characteristics is more beneficial than a treatment 
based on primary tumor characteristics.  
Whenever a certain treatment has been started based on miRNA expression data, re-assessment can occur 
each time the patient becomes refractory to the installed treatment. Acquired resistance to systemic anti-tumor 
treatment is a major problem in cancer treatment, and overcoming that resistance by administering targeted 
therapy based on changed tumor characteristics might greatly improve patients’ prognosis. 
 
4.3 Circulating miRNAs as a monitorable drug target 
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One of the big theoretical advances of targeting miRNAs is the ability to monitor their expression in the 
circulation. When anti-miRNA treatment is started, miRNA expression levels could be monitored in blood at 
various time points, and their increase could predict treatment resistance and warrant a switch in therapeutic 
regimen. Already, it was shown that the administration of intravenous anti-miR-16, anti-miR-122, anti-miR-192 
and anti-miR-194 caused a decrease in the levels of the corresponding miRNAs across all organs in mice[45]. 
In this sense, circulating miRNAs could serve as combined drug targets and pharmacodynamic markers. 
 
5. Cell-free circulating miRNAs 
In view of the potential advantages of determining miRNA expression in the peripheral circulation over that in 
primary tumor tissue, several studies have already identified free circulating miRNAs that are expressed in the 
circulation of cancer patients. Importantly, most of these miRNAs were found to be differentially expressed 
between cancer patients and healthy donors. These miRNAs were found to be either diagnostic or prognostic, 
but little study has been done on their potential roles as predictive factors or drug targets. The main findings of 
the studies on circulating miRNAs in relation to diagnosis and prognosis are reviewed below and summarized 
according to 12 different primary tumor types in Table 1. We have focused on solid tumors for this review, and 
refer to Fabbri et al.[46] for a comprehensive review of the many research advances in the field of miRNAs in 
hematological malignancies. 
 
5.1. Carcinomas of unknown primary 
MiRNAs can serve to determine the tissue of origin for cancers of unknown primary origin, as has been shown 
with a classifier based on 48 miRNAs determined in primary or metastatic tumor tissue [31,32]. Lodes et al. 
focused on the evaluation of miRNA expression patterns in human serum for five types of human cancer, 
prostate, colon, ovarian, breast and lung, using a pan-human microRNA, high density microarray, and identified 
a serum classifier based on 28 circulating miRNAs able to separate cancer cases from normal individuals[47]. 
In serum of cancer patients, specific miRNA expression patterns for lung cancer and colorectal cancer have 
been identified[19], providing evidence that miRNAs present in the circulation contain fingerprints for various 
diseases.  
5.2 Breast cancer 
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In 148 breast cancer patients and 44 healthy controls, seven candidate miRNAs were measured in whole blood 
by RT-PCR without a preceding enrichment step. All miRNAs could be measured in patients and controls alike, 
but miR-195 and let-7a were expressed higher in breast cancer patients than in controls, with a mean fold 
change of 19 and 11, respectively. Additionally, the levels of these two miRNAs decreased significantly after 
curative tumor resection[48]. 
The first study that reported circulating miRNAs as potential biomarkers of early stage breast cancer with 
different results for Caucasian American (CA) versus African American (AA) women, concerns the study of 
Zhao and co-workers. After comparing levels of circulating miRNAs in plasma samples of 20 patients with early 
stage breast cancer and 20 matched controls, they reported 17 upregulated and 14 downregulated miRNAs in 
the 10 CA women and 9 upregulated and 9 downregulated miRNAs in the 10 AA women. Furthermore, they 
were able to link these differentially expressed miRNAs to specific pathways using target prediction algorithms 
[49]. 
In a larger study evaluating miR-21 expression in the serum of 102 breast cancer patients and 20 healthy 
controls, this miRNA was found to be higher expressed in patients, especially in stage IV breast cancer[23]. 
Recently, 4 breast cancer associated miRNAs were measured in the serum of 59 localized breast cancer 
patients after primary tumor surgery, 30 metastasized breast cancer patients and 29 healthy controls. MiR-10b, 
miR-34a and miR-155 discriminated metastasized breast cancer patients from controls, and the latter was 
higher expressed in localized breast cancer patients than healthy controls but also than metastasized breast 
cancer patients[50]. Another study measured three miRNAs (miR-16, miR-145 and miR-155) in the serum of 13 
breast cancer patients and 8 healthy controls, but did not find a difference in expression between these two 
groups[51]. 
5.3 Non-small cell lung cancer 
Hu et al. used serum of NSCLC patients to look for miRNAs that were differentially expressed between 30 
patients with longer survival and 30 patients with shorter survival, matched by age, sex and stage. Eleven 
miRNAs were found to differ more than five-fold between the two groups, and four of those were confirmed by 
RT-PCR to be associated with survival, also in a larger validation set of 243 NSCLC patients. While these data 
are very encouraging, the investigators unfortunately measured these miRNAs in only one healthy donor, and 
their specificity for NSCLC is thus not sufficiently clear[52]. A comparison with more healthy controls was done 
with a pooled sample of 11 Chinese lung cancer patients, in whom 28 miRNAs were downregulated and 63 
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miRNAs were upregulated compared to 11 male and 10 female normal controls. Two of the highest expressed 
miRNAs, miR-25 and miR-223, were validated in an independent set of 152 lung cancer sera and 75 normal 
sera and also found to be higher expressed in these patients[19]. 
A different approach was used by Silva et al, who preceded their tests by an EpCAM-based immunomagnetic 
enrichment step. Out of 365 candidates, no miRNAs were found to be upregulated in 28 patients as compared 
with 20 controls, but 10 miRNAs were downregulated. Three of these were differentially expressed in the 
validation step as well, and lower levels of let-7f were associated with shorter overall survival, while patients 
with lower levels of miR-30e-3p had shorter disease-free survival, without difference in overall survival[53]. 
5.4 Prostate cancer 
In prostate cancer patients, a panel of six candidate miRNAs, selected on their expression in prostate tumors 
and lack of expression in healthy donor blood, was analyzed in two pools of 25 metastatic prostate cancer 
patients and 25 healthy controls, respectively. After out of the candidate miRNAs, miR-141 showed the greatest 
differential expression between the two pools, this miRNA was confirmed to be higher expressed in cancer 
patients on an individual level as well[21].  
Brase and co-workers unfortunately did not validate their interesting findings of the upregulation of 5 miRNAs 
out of a panel of 667 candidate miRNAs in the serum of prostate cancer patients in healthy controls. They did 
observe that the expression of two of the 5 miRNAs, miR-375 and miR-141, was upregulated in malignant 
prostate tissue compared to benign prostate tissue, but concerns about the specificity of these miRNAs in 
serum remain[54]. 
Using an array method, Moltzahn and co-workers screened the expression level of 384 miRNAs in 12 healthy 
controls and 36 prostate cancer patients divided into three groups according to a validated risk score. The 
twelve miRNA candidates that were most differentially expressed between cancer patients and controls were 
validated by individual qRT-PCR, which confirmed the differential expression of nine miRNAs. No significant 
correlation was seen with risk scores or other clinicopathological parameters[55]. 
Lodes et al. used microarray profiling and found 15 miRNAs to be over-expressed in serum from 6 prostate 
cancer patients (all stage 3 and 4) relative to expression in 8 normal male controls[47]. 
5.5 Ovarian cancer 
In ovarian cancer too, interest has been generated to detect miRNAs in the peripheral blood of cancer patients. 
Comparing 9 serum samples from ovarian cancer patients to 4 serum samples from healthy donors, 21 
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differentially expressed miRNAs were identified. Eight could be confirmed in 19 cancer versus 11 normal 
specimens to be differentially expressed by RT-PCR, of which 5 (miR-21, -29a, -92 -126 and -29a) were 
upregulated expression in cancer patients, probably making these more suitable for clinical implementation[56]. 
MiRNA expression was also measured in EpCAM-positive exosomes. Exosomes are organelles that are 
actively released by tumors into the peripheral circulation and it was hypothesized that miRNAs detected in 
exosomes reflect those present in CTCs. Exosomes were isolated from 50 ovarian cancer patients and 20 
controls using an immunomagnetic enrichment method based on anti-EpCAM. Eight miRNAs were found to be 
differentially expressed between the two groups[22]. 
5.6 Gastric cancer 
Analyzing plasma samples of 69 gastric cancer patients taken before surgery and 30 healthy donors, five 
miRNAs were found to be differentially expressed[57]. Two of these five, miR-106a and miR-17, were also 
identified in samples of 90 patients (of which, remarkably, 49 were taken after resection of the primary tumor), 
to be differentially expressed compared to 27 healthy donors. Both miRNAs were expressed at a lower level 
after surgery compared to before surgery, but still differed about 10-fold from healthy controls[58]. 
As part of a larger study looking at liver pathology-specific miRNAs, gastric cancer patients were also evaluated 
for differential miRNA expression compared to controls. MiR-885-5p, which was also found to be upregulated in 
hepatocellular carcinoma patients (see below), was higher expressed in gastric cancer patients[59] compared 
to controls. 
5.7 Hepatocellular carcinoma 
MiR-500 was identified as highly expressed during fetal liver development and thus postulated to be involved in 
proliferation. Indeed, miR-500 was highly expressed in hepatocellular carcinoma cell lines, but its expression 
was higher in only 18 of 40 hepatocellular carcinomas compared to adjacent non-tumorous tissue, and in the 
serum of 3 of ten HCC patients[60]. 
Another study looking at HCC identified miR-885-5p as a miRNA of interest in this disease, being expressed 
higher in HCC patients than in healthy controls, liver cirrhosis and chronic hepatitis B patients[59]. 
5.8 Colorectal cancer 
At least three studies have looked into the occurrence of selected candidate miRNAs in the plasma of colorectal 
cancer patients. A large study looked at samples from 120 primary colorectal cancer patients and 37 advanced 
adenoma patients, both taken before surgery, and compared them to 59 age-matched healthy controls who 
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were confirmed to be without colorectal cancer by extensive diagnostic procedures including colonoscopy and 
CT scan. Two miRNAs, miR-29a and miR-92a, were identified from a training set and confirmed in the larger 
validation set to be upregulated in CRC plasma compared to controls. In adenoma patients too, these miRNAs 
were expressed higher than in controls, but significantly lower than in true cancer patients. Additionally, these 
two miRNAs decreased after surgery in another 20 colorectal cancer patients, suggesting that these miRNAs 
are in fact cancer-specific[61].  
Another study also found MiR-92a to be higher expressed in CRC patients. Five miRNAs were selected based 
on higher expression in CRC plasma compared to healthy control plasma and higher expression in primary 
cancerous biopsies compared to adjacent non-cancerous colon tissue. Of these miRNAs, the two that were 
significantly elevated in 25 CRC patients compared to controls and decreased after tumor resection (miR-92a 
and miR-17), were validated in an independent cohort of 90 CRC patients and 50 controls. Additionally, both 
miR-92a and miR-17 were not expressed higher in patients with gastric cancer or inflammatory bowel disease, 
confirming their specificity[62]. 
Pu et al. chose to investigate miR-221 out of three miRNAs abundantly expressed in CRC, because of the good 
linearity in spiking samples obtained with this miRNA. In 103 CRC patients, miR-221 expression was higher 
than in 37 controls, however with a low specificity of 41% at the optimal cut-off level. MiR-221 expression did 
correlate with overall survival and p53 expression[63]. 
5.9 Pancreatic cancer 
In pancreatic cancer, two miRNAs, miR-200a and miR-200b, involved in epithelial mesenchymal transition, 
were identified to be hypomethylated and overexpressed in primary tumors compared to surrounding normal 
pancreas tissue. In 45 serum samples obtained from pancreatic cancer patients before surgery, both miRNAs 
were expressed at a higher level than in samples from 32 healthy controls and 11 chronic pancreatitis 
patients[64]. 
Ho et al. looked for pancreatic cancer-specific expression of miR-210 in the circulation, as this miRNA 
increases under hypoxic conditions, which are known to correlate with poorer prognosis. miR-210 expression 
was measured in the plasma of a total of 22 locally advanced pancreatic cancer patients and 25 age-matched 
healthy controls, and confirmed to be 1.7–4-fold higher expressed in the patients[65].  
5.10 Head and neck cancer 
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Wong et al. examined the expression of a large panel of miRNAs in tongue carcinomas and paired normal 
tissues, which identified 24 up regulated and 13 down regulated miRNAs. Because of its 59-fold higher 
expression in tumor tissue, miR-184 was further validated in an independent dataset and observed to be more 
abundant in plasma of patients with tongue squamous cell carcinoma than in controls. Additionally, miR-184 
levels dropped after resection of the primary tumor[66]. 
5.11 Esophageal squamous cell carcinoma (SCC) 
In esophageal SCC, one large study was recently published in which 25 miRNAs measured in serum were 
found to be upregulated in a pool of 141 cancer patients compared to controls. Of these 25, 7 miRNAs were 
confirmed to be differentially expressed by individual qRT-PCR in a separate patient cohort, yielding higher 
AUCs than carcinoembryonic antigen (CEA)[67]. 
5.12 Rhabdomyosarcoma 
Besides carcinomas, research has also been focused on specific miRNAs in rhabdomyosarcoma (RMS). 
Looking at RMS cell lines and primary tumor tissues, miR-206 was found to be most abundantly expressed 
among several muscle-specific miRNAs. MiR-206 was also the marker with the highest sensitivity and 
specificity in discriminating 10 RMS-patients from 28 patients with other pediatric tumor and 17 healthy donors, 
but miRs-1, 133a and 133b, involved in muscle proliferation and differentiation[68], were also higher expressed 
in RMS patients than in controls or non-RMS patients[69]. 
 
6. CTC-associated miRNAs 
6.1 The need for CTC-specific miRNAs detection 
As depicted above, studies on cell-free circulating miRNAs yield very interesting results and show the 
measurement of miRNAs in the circulation to be both feasible and clinically relevant. However, it is to be 
expected that not all miRNAs can actually be measured in the peripheral circulation. Especially in view of the 
fact that at least 100 different miRNAs already circulate in the blood of healthy donors [19,49], it is very likely 
that measuring these miRNAs in whole blood, serum or plasma from cancer patients can yield false-positive 
results. Several studies have identified circulating miRNAs that are differentially expressed between patients 
and healthy donors (Table 1). Most of these studies have measured miRNAs in the serum, plasma or exosome 
fractions of blood, instead of using whole blood. Using serum or plasma does for the most part eliminate the 
leukocyte background present in whole blood, but evidence has been presented that most miRNAs measured 
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in these fractions are not actually derived from circulating epithelial cells[21]. Also, cellular miRNA expression 
patterns can differ from miRNA patterns released into the blood[70]. These studies raise the concern that cell-
free miRNAs present in the circulation may not be a reliable representation of metastatic or primary tumor 
tissue, and that measuring CTC-associated miRNAs would be preferable. Besides possibly better representing 
the tumor load, measuring miRNAs in CTCs has the additional benefit of being able to correlate a miRNA signal 
to a CTC count, which aids in the interpretation of epithelial specificity. 
 
6.2 Enrichment of CTC-specific miRNAs 
When testing whether identified cell-free miRNAs can be measured in CTCs, or identifying new CTC-
associated miRNAs, an enrichment step is pivotal. Most methods aimed at specifically molecularly 
characterizing CTCs in whole blood are preceded by such an enrichment step. Many methods are available, 
including enrichment based on size, density or specific marker expression[71]. These enrichment steps aim to 
isolate all CTCs from full blood, while getting rid of as many contaminating peripheral blood mononuclear cells 
(PBMCs) as possible. However, even when applying tumor-specific marker enrichment, hundreds to thousands 
of leukocytes are still present in the CTC-enriched fraction[12]. Also, the actual number of leukocytes may differ 
depending on tumor stage[50]. These leukocytes generate a background signal and thus complicate the 
measurement of CTC-specific miRNA expression, as only epithelial-specific miRNAs that are hardly expressed 
in leukocytes can be reliably measured. Many efforts are being made to develop a CTC isolation method that 
provides a purer CTC fraction for downstream analysis, based on for instance micromanipulation 
techniques[72]. Obtaining a higher purity of the enriched CTC fraction through more specific CTC isolation 
techniques would eliminate the need to only measure epithelial-specific genes, i.e., genes that are much higher 
expressed in CTCs than in leukocytes. So far, however, these techniques have not become widespread 
available and need further validation. 
Despite these challenges, measuring CTC-associated has proven to be feasible. In our own work (manuscript 
submitted), we were able to identify 10 miRNAs more abundantly expressed in patients with >5 CTCs 
compared to patients without detectable CTCs and healthy donors. 
 
6.3 Remaining technical issues concerning the measurement of CTC specific miRNAs 
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It is to be expected that the development of enrichment methods that provide a purer CTC fraction will simplify 
the measurement of CTC-associated miRNAs. In the meantime, a number of aspects need to be taken into 
consideration when measuring these CTC-specific miRNAs. Because of the low numbers of CTCs in the 
circulation, frequently less than 5 CTCs in 7.5 mL blood[73], sensitive RNA isolation techniques and unbiased 
pre-amplification steps are needed. Fortunately, kits are now on the market which enable the isolation of DNA, 
large RNA fragments (mRNA, >200 bp), small RNA fragments (micro- and non-coding RNA, <200 bp) and 
proteins in 4 separate aliquots from as little as one cell (Figure 2). After this sensitive fractionated RNA 
isolation, it is crucial that only epithelial-specific miRNAs are measured that are not or very weakly expressed in 
leukocytes. To estimate the ratio of the tumor cell-specific signal over leukocyte-derived signal, which is 
unfortunately present even after enrichment procedures, transcript levels of CTCs-specific miRNAs such as 
those in the miR-200/141 family[21,74] and leukocyte-specific miRNAs such as miR-429 can be compared[74]. 
The suitability of any miRNA combination to estimate epithelial-specific signal does however depends on the 
epithelial tumor cell type or subtype studied. Furthermore, due to the presence of cell-free EpCAM-positive 
exosomes in serum[22], it remains to be established which part of the miRNA signal from EpCAM-enriched 
CTC-fractions is actually derived from CTCs and which part from other EpCAM-enriched cells or cell fragments 
including exosomes. Another factor complicating miRNA measurement is the lack of an established 
constitutively expressed set of reference miRNAs that can be used to normalize candidate miRNA expression 
levels. MiR-16 has been used as a reference in several studies[23,50], but concerns have been raised due to 
its inconsistent expression in sera [47]. RNU/SNORs are also frequently used (Table 1), but it needs to be 
realized that these small RNA’s are longer than the actual mature miRNAs being studied, making them less 
suitable for normalization. Furthermore, RNU6B (U6) has been reported to be degraded in serum samples[67]. 
Until consensus has been established on a robust reference miRNA set, normalizing on the mean expression of 
all expressed and CTC-specific miRNAs is probably the optimal method when multiple miRNA transcripts are 
measured at the same time[75]. In Figure 2 we summarize the steps that need to be taken to ensure epithelial 
tumor cell specific gene expression profiling of CTCs.  
 
7. Concluding remarks 
When critically looking at the data generated thus far measuring miRNA expression in the circulation, a few 
remarks must be made.  
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Firstly, the methods that are used to identify differentially expressed miRNAs vary greatly; many researchers 
start off with candidate miRNAs of interest that have previously been associated with a cancer type, while 
others look at all differentially expressed miRNAs between healthy controls and patients or between tumor 
tissue and normal adjacent tissue. This latter approach also enables the identification of potential up- or 
downmodulated pathways associated with differentially expressed miRNA transcripts. Furthermore, a 
combination of several higher and lower expressed miRNAs is likely more informative than analysis of the 
expression of a single marker alone.  
Secondly, some studies have unfortunately failed to validate their results in healthy controls, raising concerns 
about the specificity of potentially interesting miRNAs. Similarly, as with CTC enumeration, and also with regard 
to gene expression profiling in CTCs, specificity is pivotal when trying to identify tumor-specific signal 
particularly when contaminating leukocytes are present. 
Lastly, any miRNA that is identified in a patient cohort to be differentially expressed or associated with 
prognosis should be validated in an independent cohort and reach acceptable sensitivity and specificity before 
it can be implemented into the clinic for routine analysis. While some studies have used validation sets, most 
have not, hampering the translation from bench to bedside. 
Despite these possible flaws in some studies, measuring circulating miRNAs, cell-free or CTC associated, has 
proven to be feasible, can generate tumor-specific results, and may thus be of clinical relevance if their 
expression can be robustly measured and is sufficiently correlated with clinical outcome parameters such as 
overall survival or therapy response. The value of circulating miRNAs is expected to increase rapidly with the 
development of techniques that are able to isolate a more pure CTC fraction. Such an improvement will enable 
the measurement of any of the discussed prognostic and predictive miRNAs that have been identified in 
primary tumor tissue. Even more so than prognostic factors, the oncology field is devoid of reliable and robust 
predictive factors that adequately guide oncologists in the choice of optimal treatment for their patients. MiRNAs 
in the circulation may provide a new opportunity in this direction because of their stability and far-stretched 
effects in cancer biology and disease progression, and research should be aimed towards identifying and 
validating the predictive potential of these markers. 
MiRNAs are a valuable addition to the information that CTCs already provide. In Figure 3 we have depicted our 
view of the future role of CTC analysis before and during treatment of cancer patients, providing both 
prognostic, predictive and drug target information at different time points. 
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8. Expert commentary 
MiRNAs have become an important research field, and have proven their value as regulators in carcinogenesis 
and cancer progression in many different cancer types. If these relatively stable small RNAs can be robustly 
detected by highly sensitive PCR methods routinely available in most laboratories, they can become a new 
class of biomarkers. More important for the clinical setting, the prognostic value of certain miRNAs has been 
established in various cancer types and data are slowly emerging on their predictive value. These clinically 
relevant miRNAs are subsequently sought for in the circulation of cancer patients to enable their repeated and 
non-invasive measurement. A few issues have to be accounted for before miRNA expression in the circulation 
as a tool to predict prognosis or therapy response is ready for the clinic.  
Firstly, consensus should be established on which fraction of peripheral blood should be used to measure 
miRNAs. Current studies have been performed in non-enriched or enriched whole blood, serum and plasma, 
without clear data being available on the distribution of miRNAs is these different blood compartments. It is 
conceivable that only a selection of miRNAs is, actively or passively, shed from circulating tumor cells. Also, the 
use of an enrichment marker for whole blood can greatly influence the amount and type of CTCs that are 
subsequently characterized.  
Secondly, more data should be generated on the occurrence and expression levels of circulating miRNAs in 
healthy individuals. This can be done either by testing selected panels of miRNAs in a large cohort of gender- 
and otherwise matched healthy controls in parallel with cancer patients.  
Thirdly, the discussion on which constitutively expressed miRNAs to use as a reference gene set is ongoing 
and it remains to be seen if a cell type-independent panel can be identified. Until that time, it is imperative that 
each study clearly states their normalization method and their reasons to choose said method. 
 
9. Five-year view 
While enumeration of CTCs has already proven its strength, the future of molecular analysis lies in the 
development of CTC isolation assays that generate higher CTC numbers and thus increased tumor DNA, 
mRNA and miRNA content, and reduce the number of contaminating leukocytes. We have already shown that 
the enrichment marker used in one of the most common CTC detection assays, the EpCAM-based CellSearch 
technique, is not expressed in all breast cancer subtypes[76]. This epithelial cell adhesion molecule (EpCAM) 
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does not detect normal-like breast cancer cells, which can however be detected by adding CD146 in the 
enrichment step[77]. This is just one example of a probably more widespread problem of marker heterogeneity 
among cancer subtypes, which causes us to miss a subset of CTCs. The development of a method that either 
uses a panel of antibodies to detect CTCs, or a method that is independent of marker expression, but instead 
on for example physical properties of tumor cells, is probably the answer to this problem. Especially the latter 
option, selecting CTCs based on unique properties such as membrane stiffness, is a still developing field[78]. 
Following this selection step by micromanipulation will enable the isolation of single CTCs, which makes them 
available for downstream applications such as whole genome DNA or transcriptome sequencing, but also 
allowing culturing of these cells. 
In a few years time, anti-miRNA treatments will probably become available, and it is very likely that at least 
some of these miRNAs will be detectable in the circulation. This could simplify and fasten the testing of these 
drugs in phase I and II clinical trials, as the level of the target miRNAs can be directly measured in the patients’ 
blood.  
 
10. Key issues 
 There is an urgent need for additional diagnostic, prognostic and predictive markers in oncology 
 These markers should preferably be measurable at any time during the course of the disease 
 Circulating tumor cells provide an unique opportunity to diagnose the origin and type of primary tumor, 
and to assess prognosis, response to therapy and drug targets non-invasively and repeatedly 
 Among these markers, miRNAs are especially promising because of their stability and pivotal regulatory 
role in carcinogenesis 
 Many miRNAs have already been identified to be of prognostic value in primary tumors 
 Some miRNAs have shown predictive value in cell lines and patients 
 Measuring miRNAs in the circulation is feasible and, depending on the choice of miRNA, can be cancer-
specific 
 A properly sized control cohort of healthy blood donors is a pre-requisite for these kind of studies 
 So far, very few circulating tumor cell associated miRNAs have been associated with prognosis or 
therapy response 
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 The technical challenge is to discriminate between epithelial tumor cell-specific miRNAs and miRNAs 
from background leukocytes 
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Figure 1: miRNA processing resulting in altered protein expression 
 
Left panel: miRNA processing 
In the nucleus, miRNAs are transcribed into primary miRNA transcripts (pri-miRNAs). These pri-miRNAs are 
subsequently cleaved into precursor miRNAs (pre-miRNAs) by Drosha. These pre-miRNAs, 70 to 90 
nucleotides in length, are transported into the cytoplasm by Exportin 5 where the hairpin precursors are cleaved 
by Dicer, resulting in a small dsRNA duplex that contains both the mature miRNA strand and its complementary 
strand. The 20 to 25 nucleotides in length mature miRNA strand is then incorporated into a RNA-induced 
silencing complex (RISC), which inhibits the function of its target mRNA by mRNA degradation or, most 
commonly, by translational repression[26,79]. (Figure freely adapted from http://www.marligen.com) 
 
Right panel: an example of the multiple functions of miR-210 in the for cancer important process of 
hypoxia, which allows cancer cells to adapt to a low oxygen environment  
Increased miR-210 expression has been linked to increased metastatic capability and increased hypoxia 
signaling in lymph node-negative estrogen receptor-positive human breast cancer[80]. MiR-210 is regulated by 
hypoxia-inducible factor 1-alpha (HIF-1alpha), and the expression of both is increased in response to hypoxia. 
By up regulating miR-210 expression during hypoxia, resulting in the repressed translation of its multiple target 
genes[79,81-88] and direct or indirect down and up regulation of downstream proteins[88], cells can adjust and 
adapt to an hypoxic environment. 
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Figure 2: Step-by-step scheme for reliable measurement of CTC-associated miRNAs 
 
After collecting blood samples in EDTA tubes to preserve RNA integrity and enrichment for CTCs (1), a 
sensitive isolation technique – preferably one that is able to isolate genomic DNA, mRNA, miRNA and protein in 
separate fractions (2) – and linear pre-amplification steps (3) are needed to enable detection of molecules in 
material from as little as one cell.  
Next, CTC- and leukocyte-specific signals are used to estimate the ratio of the tumor cell-specific signal over 
leukocyte-derived signal (4). Now, samples can be grouped into those with detectable epithelial-derived signals 
(5a) and those without detectable epithelial signals (5b), with the latter group comprising both patient samples 
without detectable epithelial signals and samples from healthy donors. Until consensus has been established 
on a robust reference miRNA set, normalizing on the mean expression of all expressed miRNAs in both groups 
(6a and 6b) is probably the optimal method when multiple miRNA transcripts are measured at the same time.  
Finally, to ensure epithelial tumor cell-specific gene expression profiling of CTCs, levels measured in the 
samples without detectable epithelial signals (6b) are used as cut-off for the samples with detectable epithelial 
signals (6a) to calculate the remaining CTC-specific signals (7).
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Figure 3: implementation of CTC enumeration and characterization into the clinic 
Here, we explain how we envision the place of CTC enumeration and characterization in the cancer 
management of the future. Before starting a new line of systemic treatment for metastatic cancer patients, CTC 
enumeration and isolation can be performed. A CTC count will clarify the prognosis of the patient, and an up-to-
date characterization of gDNA mutations and methylation, mRNA and miRNA expression and receptor status 
helps the clinician to select the most effective tumor therapy. After the first cycle of chemotherapy, CTC 
enumeration and isolation will be repeated; a rise in CTC count can be an argument to switch therapy, as is a 
switch in receptor status, acquired or loss of mutations and altered mRNA or miRNA expression. Drug targets, 
predictive and prognostic factors can be continuously reassessed during the course of treatment and at the 
time of relapse in a non-invasive manner, resulting in truly patient-tailored treatment. 
Table 1: Circulating cell-free miRNAs














1 Carcinoma of unknown primary serum no microarray 21 15 one HD 547 28 miRs no 45
2 Breast cancer no qRT-PCR 148 44 miR-16 7 miR-195 no 46
let-7a
plasma no Illumina microarray* 10 CA 10 CA 1,145 17 miRs up 14 miRs down no 47
10 AA 10 AA 9 miRs up 9 miRs down
serum no qRT-PCR 102 20 miR-16 1 miR-21 no 21
serum no qRT-PCR 89 29 miR-16 4 miR-10b miR-155 no 48
miR-34a 
3 NSCLC serum no Solexa sequencing* 2 x 30** none spiked-in miRNA 101/109*
11
3 miRs up*** 8 miRs down***
miR-1‡
50
qRT-PCR 303 1 one HD miR-486† yes
miR-30d† miR-499‡
serum no Solexa sequencing* 11** 21** total RNA 190 63 miRs up 28 miRs down 17
qRT-PCR 152 75 average of HDs 3 let-7a miR-223 no
miR-25
exosomes EpCAM-based qRT-PCR array* 28 20 miR-142-3p; miR-30b 365 0 miRs up 10 miRs down 51
qRT-PCR miR-142-3p; miR-30b 5 let-7f miR-30e-3p yes
miR-20b no
4 Prostate cancer serum no qRT-PCR 25 25 spiked-in miRNAs 6 miR-141 no 19
serum no qRT-PCR array* 21 none spiked-in miRNAs 667 69 miRs up• 0 miRs down• 52
qRT-PCR 45 none spiked-in miRNAs 5 miR-9* miR--516a-3p no
116 none spiked-in miRNAs miR-141 miR-375 yes
miR-200b no





5 Ovarian cancer serum no qRT-PCR array* 9 4 U44 & U48 365 21 miRs 54








6 Gastric cancer plasma no qRT-PCR 69 30 spiked-in miRNAs 5 miR-106a  miR-21 no 55
miR-106b let-7a
miR-17-5p
Ficoll qRT-PCR 90 27 U6 2 miR-106a no 56
miR-17
serum no qRT-PCR array 17 16 U6 5 miR-885-5p no 57
7 HCC serum no qRT-PCR 10 none U6 & total RNA 1 miR-500 no 58
serum no qRT-PCR array* 15** 10** U6 380 26 miRs up 57
qRT-PCR 46 24 U6 5 miR-885-5p no
8 Colorectal cancer plasma no qRT-PCR 100 59 miR-16 12 miR-29a no 59
miR-92a
plasma no qRT-PCR array* 25 20 U6 95 miR-17-3p miR-135b 60
miR-92 miR-222
miR-95
qRT-PCR 90 50 U6 5 miR-17-3p no
miR-92
plasma no qRT-PCR 103 37 Standard curve 3 miR-221 yes 61
9 Pancreatic cancer serum no qRT-PCR 45 32 miR-16 2 miR-200a no 62
miR-200b
plasma no qRT-PCR 22 25 spiked-in miRNAs 1 miR-210 no 63
10 Head and neck cancer plasma no qRT-PCR 30 38 miR-16 1 miR-184 no 64
11 Esophageal SCC serum no Solexa sequencing* 141** 40** total RNA na 25 miRs up 65















•higher expressed in metastatic compared to localized prostate cancer patients
HDs = healthy donors; CA = Caucasian American; AA = African American; NSCLC = non-smal cell lung cancer; HCC = hepatocallular carcinoma; SCC = squamous cell cancer; na = not 
applicable
***differentially expressed between long and short survival groups
†higher expressed in short survival group
‡higher expressed in long survival group
miR-210
Examples of proteins directly or indirectly 
modulated by miR-210
HYPOXIA
































































Collect blood sample and enrich for CTCs
5b Samples from healthy 
blood donors










7 Analyze only transcripts more highly expressed in samples





Estimate the ratio epithelial signal over leukocyte signal 
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• switch in receptor status?
CTC 
enumeration
